Skip to main content
OpenTrials
Completed

NCT Number: NCT04620941

Use of Reticulocyte Ratio and Neutrophil / Lymphocyte Ratio in the Diagnosis of Ventilator-associated Pneumonia

In this study, the utility of changes in the ratio of Ret-He and NLR as an early inflammation marker for VAP will be evaluated.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Ventilator-Associated Pneumonia (VAP) Cross Infection Disease Attributes Healthcare-Associated Pneumonia Iatrogenic Disease Infections Lung Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms Pneumonia Pneumonia, Ventilator-Associated Respiratory Tract Diseases Respiratory Tract Infections

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Mugla Sitki Kocman Universty

Muğla, Kötekli, 48000, Turkey (Türkiye)

About this study

Ventilator-associated pneumonia (VAP) is one of the most common nosocomial infections in the intensive care unit, affecting one third of patients requiring mechanical ventilation for a noninfectious reason. In the case of inflammation, iron retention increases in the reticuloendothelial system cells; hemoglobin (Hb) synthesis is reduced. It has been reported that the ratio of reticulocyte / hemoglobin (Ret-He) decreases in the early period in community-acquired pneumonia patients and may be a guide as a marker of inflammation. In addition, the neutrophil / lymphocyte ratio (NLR) is a parameter studied in the hemogram panel. It provides a clue to both the presence of infection and the focus of the infection.

In this study, the utility of changes in the ratio of Ret-He and NLR as an early inflammation marker for VAP will be evaluated.

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

-Patients who need mechanical ventilation for longer than 48 hours for a noninfectious reason in the intensive care unit

Exclusion criteria

  • Pulmonary or extrapulmonary infection before mechanical ventilation,
  • severe immunosuppression,
  • bleeding in the gastrointestinal system,
  • using corticosteroids,
  • neoplastic disease history

Treatment and study plan

reticulocyte/hemoglobin (Ret-He) ratio

Diagnostic Test

Ret-He values will be studied on the day (1st day), 4th and 7th days of the diagnosis of ventilator-associated pneumonia in patients hospitalized in the intensive care unit.

Primary outcomes

  1. Early inflammation markers for VAP

    Time frame: 7 days

    To investigate the use of NLR and Ret-He value as early inflammation markers for VAP.

Secondary outcomes

  1. morbidity and mortality

    Time frame: 7 days

    To compare the effects of Ret-He and NLR values on morbidity and mortality with other inflammation markers

Sponsors and collaborators

Lead sponsor

Muğla Sıtkı Koçman University

Other

Registry information

Important dates

Study start
2022
Primary completion
2023
Study completion
2023
First posted
Nov 9, 2020
Registry last updated
Nov 6, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.